Valuation: CASI Pharmaceuticals, Inc.

Market Cap 2.16M 1.93M 1.8M 1.64M 3.08M 208M 3.1M 21.72M 8.45M 106M 8.12M 7.94M 342M P/E 2024
-1.11x
P/E 2025 -0.33x
Enterprise Value 24.02M 21.43M 19.96M 18.16M 34.21M 2.31B 34.46M 241M 93.84M 1.18B 90.16M 88.21M 3.79B EV / Sales 2024
1.75x
EV / Sales 2025 1.9x
Free-Float
53.46%
Yield 2024 *
-
Yield 2025 -
1 week-15.63%
1 month-31.24%
3 months-28.39%
6 months-13.06%
Current year-87.62%
1 week 0.11
Extreme 0.1052
0.12
1 month 0.11
Extreme 0.1052
0.16
3 years 0.05
Extreme 0.05
8.48
5 years 0.05
Extreme 0.05
12.3
10 years 0.05
Extreme 0.05
88.92
Manager TitleAgeSince
Chief Executive Officer 62 21/07/2025
Director of Finance/CFO 44 16/05/2025
Chief Operating Officer 54 01/01/2017
Director TitleAgeSince
Director/Board Member 62 01/04/2013
Director/Board Member 50 21/03/2023
Director/Board Member 59 21/03/2023
Change 5-day change 1-year change 3-year change Capi.($)
-10.09%-34.25%-94.31%-96.24% 2.41M
+0.02%-3.52%+36.11%+111.11% 1,019B
-1.21%-6.99%+34.08%+60.96% 617B
+1.12%-0.20%+13.62%+80.24% 464B
-3.30%-6.15%+56.45%+34.69% 356B
+0.93%-1.83%+21.65%+41.43% 333B
+0.12%-4.05%+10.70%+33.53% 267B
-0.89%-5.83%-7.00%+7.91% 244B
-0.01%-3.62%+35.28%+52.02% 218B
-0.08%-4.98%+28.34%+93.61% 179B
Average +0.21%-3.74%+13.49%+41.93% 410.8B
Weighted average by Cap. +0.44%-3.63%+28.50%+68.49%

Financials

2024 2025
Net sales 28.54M 25.46M 23.72M 21.58M 40.65M 2.75B 40.95M 287M 111M 1.4B 107M 105M 4.51B 20.71M 18.48M 17.21M 15.67M 29.5M 1.99B 29.72M 208M 80.93M 1.02B 77.75M 76.08M 3.27B
Net income -39.26M -35.02M -32.63M -29.69M -55.92M -3.78B -56.33M -394M -153M -1.93B -147M -144M -6.2B -48.06M -42.87M -39.94M -36.35M -68.45M -4.63B -68.96M -483M -188M -2.36B -180M -177M -7.59B
Net Debt 6.05M 5.4M 5.03M 4.58M 8.62M 583M 8.68M 60.76M 23.64M 297M 22.71M 22.22M 956M 21.85M 19.5M 18.16M 16.53M 31.13M 2.1B 31.36M 219M 85.39M 1.07B 82.04M 80.27M 3.45B
Logo CASI Pharmaceuticals, Inc.
CASI Pharmaceuticals Inc is a holding company principally engaged in developing and commercializing innovative therapeutics and pharmaceutical products. The Company’s main business is engaged in acquiring, developing and commercializing products that augment its hematology oncology, autoimmune and organ transplant rejection therapeutic area focus as well as other unmet medical need. The Company’s main products include EVOMELA (Melphalan for Injection), FOLOTYN (Pralatrexate), CNCT19, BI-1206, CB-5339, CID-103, Thiotepa and others. The Company mainly conducts its business in the domestic market.
Employees
-
Date Price Change Volume
05/10/26 USD 0.1052 -10.09% 201
02/10/26 USD 0.1170 0.00% 1,025
01/10/26 USD 0.1170 - 3,259
30/09/26 USD 0.000000 -100.00% 126
29/09/26 USD 0.1147 -8.01% 273

Quarterly revenue - Rate of surprise